Otsuka Pharmaceutical
To see an up-to date selection of historical analyses and insights on
Otsuka Pharmaceutical,
visit our
new, dynamically updated Company Summary report pages for Otsuka Pharmaceutical.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Otsuka Pharmaceutical are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Otsuka Pharmaceutical,
or on any other Company covered by EvaluatePharma® Contact Us today.
CONSENSUS FORECASTS ($US mln) - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
Annual Sales WW - Sales |
Growth per Year (%) |
|
|
Rank |
Product |
Generic Name |
Pharmacological Class |
2006 |
2007 |
2007 |
| Otsuka Pharmaceutical |
1 |
Abilify |
aripiprazole |
5HT1A (serotonin) & D2 partial agonist & 5HT2 (serotonin) receptor antagonist |
1,957 |
2,638 |
|
35% |
|
|
|
2 |
Pletal/Pletaal |
cilostazol |
Phosphodiesterase III inhibitor |
308 |
354 |
|
15% |
|
|
|
3 |
Mucosta |
rebamipide |
Anti-ulcerant |
290 |
310 |
|
7% |
|
|
|
|
|
Note: Shaded Cells |
|
|
|
|
PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
|
|
Rank |
Product |
Therapeutic Category |
Therapeutic Subcategory |
Pharmacological Class |
Phase (Current) |
| Otsuka Pharmaceutical |
- |
Samska (OPC-41061) |
Cardiovascular |
Diuretics |
V2 vasopressin antagonist |
Filed |
|
|
- |
OPC-6535 |
Gastro-Intestinal |
Gastro-intestinal anti-inflammatories |
Phosphodiesterase IV inhibitor |
Phase III |
|
|
- |
OPC-51803 (SOU-003) |
Genito-Urinary |
Other genito-urinary agents |
V2 vasopressin agonist |
Phase I |
|
|
|
DEALS - Selected Company Deals
|
|
|
|
|
Rank |
Deal Date |
Deal Type |
Product |
Status on Deal Date |
Deal Partner/ Product Source |
Deal Value |
| Otsuka Pharmaceutical |
1 |
Sep 2008 |
In-licensed |
ACU-4429 |
Phase I |
Acucela |
290 |
|
|
2 |
Mar 2008 |
In-licensed |
Kinase Inhibitors Research Project |
Research project |
MethylGene |
60 |
|
|
3 |
Jul 2007 |
In-licensed |
CNS Research Programme |
Research project |
GW Pharmaceuticals |
11 |
|
|
|
FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
|
| Otsuka Pharmaceutical |
|
|
2005 |
2006 |
| Valuation Measures |
| Based on Latest Share Prices |
| Valuing the Equity |
|
|
| Valuing the Enterprise |
| Free Cash Flow (Pre-Dividends) |
322 |
436 |
|
|
| Forecast Financials |
| Income Statement |
| Total Revenues |
6,661 |
7,305 |
| Cost of Goods Sold |
(2,546) |
(2,668) |
| S,G & A |
(2,677) |
(2,954) |
| R&D |
(917) |
(900) |
| Other Income/ Expense - Net |
45 |
108 |
| Associate/ Equity Affiliate Income |
52 |
53 |
| EBIT - Normalised |
617 |
943 |
| Net Interest & Financial Items |
16 |
31 |
| Pre-tax Profits - Normalised |
633 |
975 |
| Exceptionals |
(49) |
(14) |
| Income Before Taxes |
585 |
961 |
| Tax |
(231) |
(353) |
| Tax Rate (%) |
39.6% |
36.8% |
| Minorities |
(118) |
(155) |
| Net Income - Reported |
235 |
452 |
| Net Income - Normalised |
265 |
461 |
|
|
| Per Share Data |
| EPS - Diluted |
2.35 |
4.52 |
| EPS - Basic |
2.35 |
4.52 |
| EPS - Normalised (diluted) |
2.65 |
4.61 |
| EPS - Normalised (basic) |
2.65 |
4.61 |
| Avg. Shares Outstanding - Diluted |
100.0 |
100.0 |
| Avg. Shares Outstanding - Basic |
100.0 |
100.0 |
| DPS |
0.08 |
0.09 |
|
|
|
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| Zosyn® to be Launched in Japan on October 1: An Injectable Antibiotic Combination Product Consisting of Semisynthetic Antibiotic and ß-lactamase Inhibitor
|
(Toyama Chemical)
|
30-Sep-2008 |
| Zosyn® to be Launched in Japan on October 1: an Injectable Antibiotic Combination Product Consisting of Semisynthetic Antibiotic and ß-lactamase Inhibitor
|
(Taisho Pharmaceutical)
|
30-Sep-2008 |
| Sanofi-Aventis Announces the Termination of Development and Commercialization Agreement for S-1 With Taiho Pharmaceutical
|
(Sanofi-Aventis)
|
18-Jul-2008 |
| Positive Outcome to Helsinn’s Participation in the 2008 ASCO Annual Meeting Chicago, USA, 30 May – 3 June 2008
|
(Helsinn Healthcare)
|
16-Jun-2008 |
| MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
|
(MethylGene)
|
02-Jun-2008 |
| Santarus Announces Development Program for New ZEGERID Prescription Product
|
(Santarus)
|
28-May-2008 |
| Positive Clinical Data with Santarus' ZEGERID Capsules in Controlling 24-Hour Gastric Acidity Presented in DDW Abstract
|
(Santarus)
|
19-May-2008 |
| ABILIFY(R) (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (Aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (Aged 13-17) With Schizophrenia
|
(Bristol-Myers Squibb)
|
08-May-2008 |
| U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features
|
(Bristol-Myers Squibb)
|
08-May-2008 |
| Abilify® (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (aged 13-17) With Schizophrenia
|
(Otsuka Pharmaceutical)
|
08-May-2008 |
| U.S. Food and Drug Administration Approves Abilify® (aripiprazole) for Add-on Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features
|
(Otsuka Pharmaceutical)
|
08-May-2008 |
| MethylGene Presents Clinical Biomarker Data for MGCD0103 and Preclinical Efficacy Data in Combination With Taxanes at AACR Annual Meeting
|
(MethylGene)
|
14-Apr-2008 |
| Bristol-Myers Squibb and Otsuka Receive European Marketing Authorisation for Abilify® in the Treatment and Prevention of Moderate to Severe Manic Episodes in Bipolar I Disorder
|
(Otsuka Pharmaceutical)
|
08-Apr-2008 |
| Abraxis BioScience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
|
(Abraxis BioScience)
|
17-Mar-2008 |
| U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated with Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
|
(Bristol-Myers Squibb)
|
29-Feb-2008 |
| U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
|
(Otsuka Pharmaceutical)
|
29-Feb-2008 |
| Bristol-Myers Squibb and Otsuka Receive Positive CHMP Opinion for Abilify® (aripiprazole) in Bipolar I Disorder
|
(Otsuka Pharmaceutical)
|
22-Feb-2008 |
|
|
|
IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
|
|
|
|
|
Product |
Generic Name |
| Otsuka Pharmaceutical |
Abilify |
aripiprazole |
|
|
Abraxane |
paclitaxel & albumin |
|
|
Acalas |
prandipine |
|
|
ACU-4429 |
- |
|
|
Acuatim/Nadixa |
nadifloxacin |
|
|
Aminoleban EN |
amino acids |
|
|
Arkin-Z |
vesnarinone |
|
|
Busulfex |
busulfan |
|
|
Cimzia |
certolizumab pegol |
|
|
CNS Research Programme |
- |
|
|
Ethynylcytidine |
ethynylcytidine |
|
|
FerriSeltz |
ferric ammonium citrate |
|
|
Hi-Z |
gamma oryzanol |
|
|
IPD |
suplatast tosilate |
|
|
Kadian |
morphine sulfate |
|
|
Keppra |
levetiracetam |
|
|
Kinase Inhibitors Research Project |
- |
|
|
Lorelco |
probucol |
|
|
Meptin/Onsukil |
procaterol |
|
|
Meropen (kit) |
meropenem |
|
|
Metabolic Research Project |
- |
|
|
Mikelan Eye Drops |
carteolol |
|
|
Mikelan/Mikelan LA |
carteolol |
|
|
Mucosta |
rebamipide |
|
|
Myocalm |
piracetam |
|
|
Nitrolingual Pumpspray |
nitroglycerin |
|
|
NO-1886 |
ibrolipim |
|
|
Ogamma 100 |
interferon gamma |
|
|
OIF |
interferon alfa |
|
|
Oncology Research Programme |
- |
|
|
OPB-2045G |
olanexidine |
|
|
OPB-31121 |
- |
|
|
OPC-14523 |
- |
|
|
OPC-246 |
calcitonin |
|
|
OPC-28326 |
- |
|
|
OPC-32508 |
- |
|
|
OPC-51803 (SOU-003) |
- |
|
|
OPC-6535 |
tetomilast |
|
|
OPC-67683 |
- |
|
|
Opso |
morphine hydrochloride |
|
|
OraVescent Fentanyl |
fentanyl |
|
|
Oronine-H |
oronine |
|
|
Otsuka CEZ Injection-MC |
cefazolin |
|
|
Ozex |
tosufloxacin |
|
|
Palavale |
econazole |
|
|
Palonosetron |
palonosetron |
|
|
Peptide Vaccine |
- |
|
|
Physuline |
mozavaptan |
|
|
Pletal/Pletaal |
cilostazol |
|
|
Prink Injection Syringe |
alprostadil |
|
|
Raxar/Vaxar |
grepafloxacin |
|
|
Rebamipide ophthalmic suspension |
rebamipide |
|
|
Rotigotine CDS |
rotigotine |
|
|
Samska (OPC-41061) |
tolvaptan |
|
|
Sativex |
nabiximols |
|
|
Saxagliptin |
saxagliptin |
|
|
Saxagliptin & Metformin |
saxagliptin & metformin |
|
|
Synaclyn |
flunisolide |
|
|
Tazocin |
piperacillin & tazobactam |
|
|
Toboron |
toborinone |
|
|
Trehalose |
- |
|
|
TS-1 |
tegafur |
|
|
UFT |
tegafur & uracil |
|
|
Undisclosed Therapeutic Product |
- |
|
|
Uniphyl |
theophylline |
|
|
Urepearl/Urepearl L |
urea |
|
|
Utefos |
tegafur |
|
|
UZEL |
folic acid |
|
|
Vitrase |
hyaluronidase (ovine) |
|
|
Zegerid |
omeprazole |
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
